All Articles

Beneath the headline loss, Daily Journal's tech subsidiary is flourishing. How does this dual identity shape its future in a post-Munger world?

A Pasadena firm's Inc. 5000 rank reveals a deeper story: how a client-first, fee-only fiduciary model builds unshakeable trust and sustainable success.

BGMS is pivoting from fire safety via a reverse merger with Future NRG. The deal gives NRG shareholders 99% control, creating a new environmental services giant.

After a rocky Q1, Ellington Credit Company's active strategy in the volatile CLO market paid off, delivering strong returns and a blueprint for resilience.

Marchex's standalone revenue is falling, but its major AI acquisition, Archenia, is already boosting its outlook. Can this strategic pivot deliver lasting value?

While Q2 earnings reflect a tough construction market, Omega Flex's strategic CE Mark for its MediTrac tubing opens a new European front for growth.

With key FDA backing and promising clinical data, Allogene Therapeutics is advancing a vision where complex cell therapies are not just for major medical centers.

With pivotal data due in September, Connect Biopharma's rademikibart could redefine acute asthma and COPD care. Can it navigate this clinical tightrope?

BioCardia secures key regulatory backing in the US and Japan, but the real story may be its pivot to a platform provider for the entire cardiac biologics field.

Atea's promising Hep C drug offers a shorter, simpler regimen for complex patients, but faces a tough market. Meanwhile, the firm tackles a neglected virus.

Nordique Critical Metals advances its key rare earth project, but faces a crucial test balancing promising economics against significant environmental and community hurdles.

Despite grim Q2 financials, Perma-Fix secures a key role in the massive Hanford cleanup, a multi-billion dollar gamble that could define its future.

Starlight's Western Canada fund posted a net loss, but a 102% jump in key cash flow metrics reveals a booming operation fueled by a major acquisition.

Liftoff Mobile reported a net loss, but a look past the IPO-related accounting reveals a company firing on all cylinders, with its AI platform driving record revenue.

Genomic pioneer Sangamo sells key assets to PTC and Lilly in a $163M bankruptcy deal, reshaping the future of gene therapy and rare disease treatment.

A 30% revenue dip masks a strategic pivot at OptimizeRx. Inside the numbers, a story of disciplined debt management and a bold bet on AI innovation emerges.

Journey Medical posts a stellar 23% revenue jump, nearing profitability. But beyond the headlines, a crucial SEC filing reveals a complex financial reality.

With pivotal lung cancer data imminent, ArriVent BioPharma juggles a high-risk, high-reward strategy, betting its future on a novel drug and a new wave of ‘smart bomb’ therapies.

Two former colleagues, Ben Brown and Wayne Watson, now co-lead BOND's AV division. This reunion isn't just sentimental—it's a calculated move for market dominance.

From the TV studio to the C-suite, four leaders are redefining wellness. NYAM's 2026 gala honors the innovators building the future of health.